Anti-PD-1 Antibody
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial (NCT05290935) | Lei Li | 2022-03-13 |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer (NCT04803851) | Peking Union Medical College Hospital | 2021-05-12 |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas (NCT04635956) | Lei Li | 2020-11-15 |
| Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer (NCT04636008) | West China Hospital | 2020-08-14 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy (NCT04188860) | Lei Li | 2019-12-06 |
Track Anti-PD-1 Antibody automatically
Every clearance here is in the API, with alerts when new ones post.